Trials / Completed
CompletedNCT03318874
Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction
Comparing the Effects of THERA°PEARL Eye Mask (Bausch & Lomb Inc., New York, USA) With the Use of Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK).
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label, randomized controlled study in a Norwegian population with meibomian gland dysfunction. Patients will be randomized to one of two groups: THERA°PEARL Eye Mask (Bausch \& Lomb Inc., New York, USA) or Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK). All patients will receive Hylo-comod (URSAPHARM Arzneimittel GmbH, Saarbrücken, Germany).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Blephasteam | Steam delivery goggles, once daily |
| DEVICE | THERA°PEARL Eye Mask | Heat delivery device, delivering heat to the eyelids, once daily |
| DRUG | Hylo-comod | Tear substitute containing hyaluronic acid, four times daily |
Timeline
- Start date
- 2017-10-19
- Primary completion
- 2020-04-15
- Completion
- 2021-11-17
- First posted
- 2017-10-24
- Last updated
- 2021-11-22
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT03318874. Inclusion in this directory is not an endorsement.